{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T18:07:34Z","timestamp":1790964454328,"version":"4.1.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2012,11,1]],"date-time":"2012-11-01T00:00:00Z","timestamp":1351728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,11,1]],"date-time":"2012-11-01T00:00:00Z","timestamp":1351728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2012,11]]},"DOI":"10.1016\/j.jaad.2012.02.010","type":"journal-article","created":{"date-parts":[[2012,4,11]],"date-time":"2012-04-11T09:31:41Z","timestamp":1334136701000},"page":"1025-1039","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":265,"title":["Grading dermatologic adverse events of cancer treatments: The Common Terminology Criteria for Adverse Events Version 4.0"],"prefix":"10.1016","volume":"67","author":[{"given":"Alice P.","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Setser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milan J.","family":"Anadkat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Cotliar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elise A.","family":"Olsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin C.","family":"Garden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario E.","family":"Lacouture","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2012.02.010_bib1","first-page":"1462","article-title":"Dermatologic challenges in cancer patients and survivors","volume":"21","author":"Agha","year":"2007","journal-title":"Oncology"},{"key":"10.1016\/j.jaad.2012.02.010_bib2","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1093\/jnci\/djp439","article-title":"Dermatologic infections in cancer patients treated with epidermal growth factor receptor inhibitor therapy","volume":"102","author":"Eilers","year":"2010","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jaad.2012.02.010_bib3","doi-asserted-by":"crossref","first-page":"3916","DOI":"10.1002\/cncr.25090","article-title":"Effects of epidermal growth factor receptor inhibitor-induced dermatologic toxicities on quality of life","volume":"116","author":"Joshi","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.jaad.2012.02.010_bib4","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.jaad.2010.06.051","article-title":"The emergence of supportive oncodermatology: the study of dermatologic adverse events to cancer therapies","volume":"65","author":"Balagula","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2012.02.010_bib5","first-page":"48","article-title":"Efficacy and skin toxicity management with cetuximab in metastatic colorectal cancer: outcomes from an oncologic\/dermatologic cooperation","volume":"7","author":"Racca","year":"2008","journal-title":"Clin Colorectal Cancer"},{"key":"10.1016\/j.jaad.2012.02.010_bib6","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S1053-4296(03)00031-6","article-title":"CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment","volume":"13","author":"Trotti","year":"2003","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/j.jaad.2012.02.010_bib7","unstructured":"NCI. CTCAE. Available from: URL:http:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/About.html. Accessed May, 17, 2010."},{"key":"10.1016\/j.jaad.2012.02.010_bib8","unstructured":"ICH harmonized tripartite guideline post-approval safety data management: definitions and standards for expedited reporting E2D, current step 4 version. International Conference of Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use. November 12, 2003."},{"key":"10.1016\/j.jaad.2012.02.010_bib9","first-page":"509","article-title":"A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group","volume":"18","author":"Lacouture","year":"2010","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.jaad.2012.02.010_bib10","first-page":"21","article-title":"Incidence of chemotherapy-induced alopecia by chemotherapy regimen: a review of published randomized trials","author":"Koo","year":"2002","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.jaad.2012.02.010_bib11","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1007\/s11095-006-9105-3","article-title":"Protection against chemotherapy-induced alopecia","volume":"23","author":"Wang","year":"2006","journal-title":"Pharm Res"},{"key":"10.1016\/j.jaad.2012.02.010_bib12","series-title":"Fitzpatrick\u2019s dermatology in general medicine","article-title":"Chapter 146, Cutaneous lymphoma","author":"Chalid","year":"2008"},{"issue":"Suppl","key":"10.1016\/j.jaad.2012.02.010_bib13","first-page":"4","article-title":"Clinical presentation and pathophysiology of EGFRI dermatologic toxicities","volume":"21","author":"Mitchell","year":"2007","journal-title":"Oncology (Williston Park)"},{"key":"10.1016\/j.jaad.2012.02.010_bib14","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1177\/1078155208100450","article-title":"Nail toxicity induced by cancer chemotherapy","volume":"15","author":"Gilbar","year":"2009","journal-title":"J Oncol Pharm Pract"},{"key":"10.1016\/j.jaad.2012.02.010_bib15","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1093\/annonc\/mdg050","article-title":"Taxane-induced nail changes: incidence, clinical presentation and outcome","volume":"14","author":"Minisini","year":"2003","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jaad.2012.02.010_bib16","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S1470-2045(05)70243-6","article-title":"Cutaneous side-effects of kinase inhibitors and blocking antibodies","volume":"6","author":"Robert","year":"2005","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jaad.2012.02.010_bib17","first-page":"494","article-title":"The hand-foot syndrome\u2013a frequent secondary manifestation in antineoplastic chemotherapy","volume":"16","author":"Janusch","year":"2006","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.jaad.2012.02.010_bib18","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.ejca.2008.01.028","article-title":"Pegylated liposomal doxorubicin-associated hand-foot syndrome: recommendations of an international panel of experts","volume":"44","author":"von Moos","year":"2008","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jaad.2012.02.010_bib19","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1093\/annonc\/mdn389","article-title":"Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib","volume":"19","author":"Lacouture","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jaad.2012.02.010_bib20","first-page":"267","article-title":"Erlotinib-induced skin rash: pathogenesis, clinical significance and management in pancreatic cancer patients","volume":"9","author":"Saif","year":"2008","journal-title":"JOP"},{"key":"10.1016\/j.jaad.2012.02.010_bib21","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1468-3083.2009.03490.x","article-title":"Cetuximab-induced cutaneous toxicity","volume":"24","author":"Tomkov\u00e1","year":"2010","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2012.02.010_bib22","doi-asserted-by":"crossref","first-page":"106","DOI":"10.3816\/CLC.2009.n.013","article-title":"Erlotinib-induced skin rash in patients with non-small-cell lung cancer: pathogenesis, clinical significance, and management","volume":"10","author":"Tsimboukis","year":"2009","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.jaad.2012.02.010_bib23","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.radonc.2007.04.034","article-title":"Acneiform rash secondary to cetuximab plus head and neck radiotherapy","volume":"85","author":"Mydin","year":"2007","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.jaad.2012.02.010_bib24","first-page":"7","article-title":"Facial acneiform rash associated with sorafenib","volume":"15","author":"Fleta-As\u00edn","year":"2009","journal-title":"Dermatol Online J"},{"key":"10.1016\/j.jaad.2012.02.010_bib25","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1007\/s10637-009-9257-1","article-title":"Phase I, pharmacokinetic study of temsirolimus administered orally to patients with advanced cancer","volume":"28","author":"Buckner","year":"2010","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.jaad.2012.02.010_bib26","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa060655","article-title":"Sorafenib in advanced clear-cell renal-cell carcinoma","volume":"356","author":"Escudier","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2012.02.010_bib27","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1056\/NEJM199512143332404","article-title":"Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis","volume":"333","author":"Roujeau","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2012.02.010_bib28","doi-asserted-by":"crossref","first-page":"288","DOI":"10.4103\/0378-6323.16628","article-title":"Imatinib induced Stevens-Johnson syndrome: lack of recurrence following re-challenge with a lower dose","volume":"71","author":"Pavithran","year":"2005","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"10.1016\/j.jaad.2012.02.010_bib29","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s10549-008-0020-7","article-title":"Analysis of dermatologic events in patients with cancer treated with lapatinib","volume":"114","author":"Lacouture","year":"2009","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.jaad.2012.02.010_bib30","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1056\/NEJM199411103311906","article-title":"Severe cutaneous adverse reactions to drugs","volume":"331","author":"Roujeau","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2012.02.010_bib31","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1093\/annonc\/mdm400","article-title":"Consensus guidelines for the management of radiation dermatitis and coexisting acne-like rash in patients receiving radiotherapy plus EGFR inhibitors for the treatment of squamous cell carcinoma of the head and neck","volume":"19","author":"Bernier","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jaad.2012.02.010_bib32","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1097\/01.SMJ.0000140866.97278.87","article-title":"Skin toxicity during breast irradiation: pathophysiology and management","volume":"97","author":"Harper","year":"2004","journal-title":"South Med J"},{"key":"10.1016\/j.jaad.2012.02.010_bib33","doi-asserted-by":"crossref","first-page":"45","DOI":"10.2165\/00128071-200607010-00005","article-title":"Cutaneous reactions to chemotherapy and their management","volume":"7","author":"Wyatt","year":"2006","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.jaad.2012.02.010_bib34","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1159\/000088510","article-title":"Severe pustular eruption associated with imatinib and voriconazole in a patient with chronic myeloid leukemia","volume":"211","author":"Gambillara","year":"2005","journal-title":"Dermatology"},{"key":"10.1016\/j.jaad.2012.02.010_bib35","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1159\/000277656","article-title":"Treatment of epidermal growth factor receptor antagonist-induced skin rash: results of a survey among German oncologists","volume":"33","author":"Hassel","year":"2010","journal-title":"Onkologie"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S019096221200134X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S019096221200134X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:25:30Z","timestamp":1759271130000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S019096221200134X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012,11]]}},"alternative-id":["S019096221200134X"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2012.02.010","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2012,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Grading dermatologic adverse events of cancer treatments: The Common Terminology Criteria for Adverse Events Version 4.0","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2012.02.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}